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Abstract Triptans, selective 5-HT1B/1D receptor ago-
nists, are specific drugs for the acute treatment of migraine
that have the same mechanism of action. Here, it is dis-
cussed why the differences among kinetic parameters of
oral triptans have proved not to be very important in
clinical practice. There are three main reasons: (1) the
differences among the kinetic parameters of oral triptans
are smaller than what appears from their average values;
(2) there is a large inter-subject, gender-dependent, and
intra-subject (outside/during the attack) variability of
kinetic parameters related to the rate and extent of
absorption, i.e., those which are considered as critical for
the response; (3) no dose-concentration–response curves
have been defined and it is, therefore, impossible both to
compare the kinetics of triptans, and to verify the objective
importance of kinetic differences; (4) the importance of
kinetic differences is outweighed by non-kinetic factors of
variability of response to triptans. If no oral formulations
are found that can allow more predictable pharmacoki-
netics, the same problems will probably also arise with new
classes of drugs for the acute treatment of migraine.
Keywords Acute treatment  Disposition  Headache 
Pharmacokinetics  Triptan  Variability
Introduction
The availability of many drugs for the management of a
disorder should allow optimising the therapy, obtaining for
individual patient maximum benefits with minimal side
effects [1]. Triptans, selective agonists at 5-hydroxytryp-
tamine 1B/1D receptor subtype, are among the few specific
drugs which are effective and safe for acute migraine
treatment [2]. Migraine is a very common disorder. Its
lifetime incidence is 18% in men and 43% in women [3].
Although migraine is not life-threatening, it often heavily
affects work and social functioning and reduces the overall
quality of life [4].
The triptans are recommended as first-line drugs for
patients suffering from moderate to severe migraine, asso-
ciated with disability, who do not respond to COX-inhibitors
[2]. Sumatriptan was the first to be marketed, at the begin-
ning of the 1990s. Even if it is fast absorbed orally, its bio-
availability is only 14% and it has a short half-life of about
2 h. Six other triptans have been later introduced: zolmi-
triptan, naratriptan, rizatriptan, eletriptan, almotriptan, and
frovatriptan, which have greater oral bioavailability, longer
plasma half-life, active metabolites, higher lipophilicity, and
greater potency and affinity for 5-HT1B/1D receptors [5].
Triptans are homogeneous in their mechanism of action [6].
It has, therefore, been thought that the differences with
respect to their pharmacokinetics can cause a different effi-
cacy, frequency of recurrence, and consistency of response,
and they can therefore allow choosing the most appropriate
triptan for each patient [7]. However, only minor differences
in the efficacy of oral triptans for migraine have been
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reported [5, 8]. In particular, the maximum response after
oral administration, measured as pain relief after 2 h, is
approximately 70% in clinical trials [9], and up to 40% of
attacks fail to respond to a particular drug [10]. Furthermore,
less than 2/3 of patients respond to a triptan in three out of
three attacks [11]. Recurrence is a common event; in triptan
trials, recurrence rates vary from 7 to 57% [12], and in
patients using triptans headache return is associated to 24%
of headaches which have had a pain-free response [13].
Indeed, 40–50% of patients report dissatisfaction with at
least one aspect of their current triptan therapy [14], there is a
marked variation in the individual patient response and
preference for the available oral triptans [15, 16], and it
seems that there are no characteristics which can make the
difference between one drug and another [17]. Moreover,
there is no clear method of choosing an appropriate oral
triptan for a particular patient and, currently, this is achieved
by trial and error [11].
Omitting pharmacodynamic aspects and the variability
of response depending on metabolism, we have analysed
here why pharmacokinetic differences among the various
oral triptans have such a limited clinical importance.
Because of the interindividual variability of kinetic
parameters
The differences among the kinetic parameters of the various
triptans are less important than what can appear from
average values (arithmetic mean, median or geometric
mean) of these parameters (Table 1). There is great inter-
individual variability of kinetic parameters, which only
emerges if, besides the average value, the standard devia-
tion (i.e., the spread of data around the expected value), and
the range of the values are also indicated. The interindi-
vidual variability is even more evident, if the coefficient of
variation (CV, allowing comparison of data sets with dif-
ferent unit measures) or the confidence interval (CI, i.e., an
interval likely to include as a parameter) is expressed. This
variability reduces the difference between a drug and
another, makes the comparison among triptans difficult, and
limits the possibility to predict with a good chance of suc-
cess the kinetics of a certain triptan in an individual patient.
Numerous kinetic parameters of triptans vary, also in a
statistically significant way, according to gender (Table 2).
In particular, Cmax (the peak plasma concentration) and
AUC0–? (the area under plasma concentrations from 0 to
infinity) of frovatriptan, naratriptan, rizatriptan, and
zolmitriptan are significantly lower in males than in
females. These differences have been partially attributed to
higher bioavailability in females and higher total body
clearance in males [18–22]. Kinetic variations according to
gender have generally received little attention from
researchers also because, according to producers, no dose
adjustment is needed depending on the patient’s gender.
This statement makes it clear the limited importance of
plasma concentrations, in particular of maximum ones, as a
parameter by itself, indicative of the response [23]. It also
Table 1 Some pharmacokinetic parameters of oral triptans
Triptan Cmax (ng/ml) AUC (ng h/ml) Tmax (h)
Almotriptan 12.5 mg [22, 54] 49.5a (13.5) 266.1a (39.1) 2.5a (0.7)
Eletriptan 20 mg [57] 61.5b (32.5–116.5) 317.3b (152.9–658.1) 1.0c (0.5–1.5)
Frovatriptan 2.5 mg [58] 4.2b M (3.19–5.61) 42.9b M (36.3–50.7) 2.3c M (2.0–2.5)
7.0b F (6.02–8.14) 65.8b F (65.8–134.3) 3.0c F (2.0–4.0)
Naratriptan 5 mg [19, 59] 10.8d M (7.1–14.2) 108.2d M (76.6–168.1) 3.0c M (2.0–6.0)
16.6d F (9.8–37.3) 163.6d F (89.9–256.5) 3.0c F (1.0–6.0)
Rizatriptan 10 mg [20, 60, 61] 28.6a M (13.5) 72a (22) 1.0a (0.5) (range: 0.6–2.4)
32.1a F (11.9) 97a (28) 1.2a (1.0) (range: 0.4–2.0)
Sumatriptan 50 mg [31] 30.1a (12.5) 103a (49) 0.83e (0.33–3.00)
Sumatriptan 100 mg [33] 53.2a (29) 199a (105) 1.0e (0.5–4.00)
Zolmitriptan 2.5 mg [18] 3.0a (1.7) 17a (8.1) 2.0c (0.5–6.0)
3.3e M 17.7e M
3.8e F 21.3e F
M males, F Females
a Arithmetic mean (±SD)
b Geometric mean (95% CI)
c Median (range)
d Arithmetic mean (range)
e Geometric mean (range)
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suggests that the differences in the mean values of the
pharmacokinetic parameters of triptans cannot predict a
different efficacy.
Because the dose-concentration–response relationship
is not definite for oral triptans
Pharmacokinetic factors will influence the disposition of a
drug in the body, and ultimately, the concentration of
unbound, or free, drug at the receptors, fundamental to the
drug’s effect. For pharmacokinetic factors to be of rele-
vance, alterations in the concentration of drug at the
receptor must cause changes in the amount of the drug
effect. In other words, a dose-concentration–response
relationship must be discernible. Most pharmacokinetic
studies have been unfortunately carried out in healthy
volunteers or migraine patients, but outside the attack.
Furthermore, the responses to the triptan in migraine attack
treatment are time-dependent [24, 25]. All triptans are
more effective, if they are taken early and when pain is
mild [26]. Also for these reasons, plasma concentrations
are not directly related to the effect and the clinical
response, and the dose-concentration–response curve has
not been defined for any oral triptan [25, 27, 28]. There-
fore, it is impossible to compare triptans and objectively
verify the importance of the differences in pharmacokinetic
parameters during the migraine attack.
Because few pharmacokinetic parameters
can be used to compare triptans
The changes in the plasma concentrations of the triptan in
the initial phase (till 2 h after administering the drug) have
been considered important to relate kinetics to clinical
response. This phase is characterised by the extent and rate
of absorption. However, the initial rate of absorption seems
to be related to the patient’s response more than the height
of the plasma concentrations reached [28–30]. The key
variable is therefore Tmax (time to peak concentration),
which indicates the rate of absorption [31]. Nevertheless,
this parameter is the one which presents the highest inter-
individual variability. The comparison between Tmax and
therapeutic gain at 2 h after administering different for-
mulations of sumatriptan (oral, rectal, intranasal, subcuta-
neous, and intravenous) shows the importance of this
parameter. An inverse relationship has been observed
between Tmax and therapeutic gain: the fewer Tmax, the
higher therapeutic gain after 2 h [32].
Cmax, AUC0–2, Cmax/Tmax, AUC0–2/AUC0–t, AUC0–?/
Tmax, and Cmax/AUC0–? have also been proposed to assess
the rate and extent of absorption [29, 33, 34]. However,
these parameters can only be used to compare different
formulations of the same triptan, and not different triptans,
since data about the time-course of plasma concentrations
in connection with the dose and response are missing, and
we do not know the minimum effective concentrations of
oral triptans which have different potency.
Because of the variability of oral absorption
An oral drug should allow, besides easy taking, an effec-
tive, fast, and predictable absorption, in order to assure a
response in most subjects. In the case of triptans, with the
same oral dose, plasma concentrations vary a lot from one
patient to another, especially in the first phase after oral
administration, i.e., the most critic one for response [35].
For example, after the administration of oral sumatriptan
Table 2 Male/female ratio of the pharmacokinetic parameters of some oral triptans
Triptan Male/female ratio of pharmacokinetic parameters
Bioavailability % Cmax (ng/ml) AUC0–? (ng h/ml) Tmax (h) Vd (L) t (h) CLp (ml/min)
Almotriptan 12.5 mg [22] NS NS NS NS – NS NS
Frovatriptan 2.5 mg [21] 0.88 0.60 0.46a 0.66–0.77 1.66 1.07 1.64
Naratriptan 5 mg [19, 59] 0.85 0.79 0.66 – – – 1.25
Rizatriptan 5 mg [20, 60, 61] – 0.96 0.78 0.77 1.31 0.92 1.27
Rizatriptan 10 mg [20, 60, 61] – 0.89 0.74 1.00 1.38 0.92 1.22
Zolmitriptan 2.5 mg [18] 1.00b 0.87c 0.83d 1.54 1.04 0.90 1.13
Zolmitriptan 5 mg [18] 0.78 0.62 0.56 – – 0.92 –
NS no statistically significant differences, – datum not available
a AUC0–12 = 0.63
b 95% CI = 0.84–1.26
c 95% CI = 0.60–1.05
d 95% CI = 0.61–1.09
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200 mg, maximum plasma concentrations varied from 52
to 227 ng/ml in healthy volunteers [34]. Plasma levels after
administering oral zolmitriptan 10 mg in migraine patients
outside the attack varied from 3 to 27 ng/ml after 2 h [36].
In addition, multiple peaks in plasma concentrations are
found in some individuals after oral administration of
sumatriptan, rizatriptan, and zolmitriptan [18, 30, 37]. The
mechanism of this phenomenon has not been explained. It
could be due to the different rates of stomach emptying or
intestinal transit [38]. After oral administration of zolmi-
triptan, the time to achieve Cmax varied from 0.5 to 6 h,
since some subjects had multiple peaks [36]. One of the
factors which influence absorption is also the rate of
stomach emptying, which is a unique characteristic of each
individual [39]. Migraineurs have delayed gastric emptying
during and between migraine attacks [40]. The variability
of absorption is very likely to increase even more during
the migraine attack when there is gastric stasis [41]. The
absorption of any triptan during the attack can therefore be
unforeseeable and erratic, and the outcome is not consistent
[28, 42, 43]. During the migraine attack (Table 3), the
amount absorbed and the plasma maximum concentration
decrease and Tmax increases. These changes in pharmaco-
kinetic parameters are statistically significant or close to
significance for some triptans. Since, in order to have a
complete response, it is fundamental to achieve sufficient
plasma levels of triptan quickly following the onset of pain,
the impairment of drug absorption may be the cause of the
therapeutic failure of an oral triptan. Indeed, when studying
the pharmacokinetics of sumatriptan following 100 mg oral
dosage, it has been noticed that 10 migraine patients with
satisfactory response to sumatriptan absorbed the drug
significantly faster and achieved significantly higher
plasma levels than patients with unsatisfactory response to
oral sumatriptan [44].
The importance of an efficient absorption for the
response is also evident if we consider that prokinetic
agents may not only be used to eliminate nausea and
vomiting, but also to promote absorption [45]. Among
migraine patients who had not got adequate relief from
triptans, 63% responded to oral sumatriptan 50 mg com-
bined with metoclopramide 10 mg, while only 31%
responded to sumatriptan administered alone [46]. In a
small sample size trial, the combination of rizatriptan and
trimebutine (another prokinetic agent) was also more
effective than rizatriptan alone [47].
Differences in plasma half-life and recurrence
It is very plausible to assume that the rate of headache
recurrence following treatments may be influenced by
kinetic properties [48]. On this basis, it has been thought
that a longer half-life causes a lower probability of recur-
rence [49]. Plasma half-life (the time it takes for the blood
plasma concentration of a substance to halve) is certainly a
parameter which can influence the duration of the action of
a drug. In spite of this, plasma half-life can be different
from biological half-life (the time it takes to halve phar-
macologic activity) due to factors such as tissue accumu-
lation, active metabolites, and strength of receptor
interactions. Furthermore, a long plasma half-life can be
clinically significant if it assures concentrations which stay
for more time within the therapeutic range [48]. Without
this information, half-life alone cannot be considered as an
indicator of the frequency of recurrence. Frovatriptan, as
all triptans, has multiexponential kinetics, but it is the one
with the longest half-life (approximately 25–26 h if cal-
culated in the final phase, up to 48–72 h after administra-
tion) [21]. This drug is also considered one of the triptans
with lower frequency of recurrence calculated from 4 h on
[49]. Frovatriptan is distributed in RBCs for 60% with a
link described as reversible and time-dependent [21].
Nevertheless, its concentrations have been determined in
whole blood, and the concentrations of the free drug, not
bound to RBCs, have not been proved to be clinically
effective. In a new analysis of data from previously pub-
lished studies, it is reported that there were no significant
differences in the frequency of relapse within 24 h after
response at 4 h, between frovatriptan 2.5 mg and suma-
triptan 100 mg, which has a half-life of only 2 h [50].
In any case, it is not completely clear which triptan is
associated to a lower frequency of recurrence. The
Table 3 During/outside migraine attacks ratio of the pharmacoki-
netic parameters of some oral triptans







Almotriptan 12.5 mga [22, 54] 0.93 1.00 1.23
Eletriptan 40 mgb [57, 62] 0.69c 0.71d 2.15e
Frovatriptan 2.5 mg [58] 0.93 M 0.53 0.66
0.91 F
Naratriptan 5 mg [63, 64] ND ND 1.75–2.33
Sumatriptan 100 mg [65, 66] 0.80f – –
Zolmitriptan 2.5 mg [18, 36] 0.75 0.56 1.6
ND no difference observed, – datum not available
a No statistically significant differences
b Statistically significant differences
c CV = 90.2% during attacks
d AUC0–8, CV = 93.8% during attacks
e CV = 77.2% during attacks
f Bioavailability
8 J Headache Pain (2011) 12:5–12
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comparison among different studies is not possible, for an
endless number of methodological problems (e.g., differ-
ences in the study design, the populations used, the char-
acteristics of the attacks, the doses administered, the
definition of recurrence, relapse or return, the methods of
registration of recurrence, and the presence of recurrence
also after the administration of placebo) [12, 49, 51].
Consequently, any result can be interpreted for or against
any medication.
Differences in bioavailability and consistency
of response
Bioavailability describes the fraction of an administered
dose of unchanged drug that reaches the systemic circula-
tion and it is one of the principal pharmacokinetic prop-
erties of drugs. It has been stressed that this parameter has a
direct relationship with the intrapatient consistency of
response of individual triptans [11, 17, 52]. For sumatrip-
tan, which has an oral bioavailability of only 14%, the
consistency of pain relief in two out of three attacks is 64%
and in three out of three attacks, 33% [53]. For almotriptan,
which has instead a higher bioavailability (70%), pain
relief in two out of three attacks is 75% and in three out of
three attacks, 50% [54]. However, even if rizatriptan has a
bioavailability of 40% (lower than almotriptan), it has a
higher consistency of response, since pain relief in two out
of three attacks is 86% and in three out of three attacks,
60% [55, 56]. Average bioavailability alone does not,
therefore, indicate the consistency of response of a specific
triptan.
It must be considered that when a medication is
administered intravenously, its bioavailability is 100%
and it does not practically vary from a subject to another.
When a medication is instead administered via other
routes (such as orally), its bioavailability is always lower
and it may vary from patient to patient, for different
factors such as gastric emptying rate, enzyme induction/
inhibition by other drugs/foods, individual variation in
metabolic enzymes, disease state affecting liver metabo-
lism or gastrointestinal function. The presence of all these
variables does not allow us to establish and foresee in
clinical practice an eventual direct relationship between
bioavailability and consistency.
Conclusions
The changes in kinetic characteristics are not always
associated to detectable changes in the relationship
between exposition and response to a drug. In the case of
Table 4 Non-pharmacokinetic factors of variability of response to triptans
Factors Description
Dynamic variability Dynamic variability can be studied in isolated tissues. In this case, a considerable variability in
the response to triptans is also observed. For example, EC50 varies 51 times for the
vasoconstrictive effect of sumatriptan on human cerebral arteries, 21 times for the effect of
rizatriptan, and 69 times for the effect of eletriptan [67]
Variability of the mechanisms implicated in the
migraine attack
During the migraine attack various mechanisms are activated. For example, only attacks
associated with elevated salivary CGRP levels respond to rizatriptan. This could explain why
some patients or attacks are non-triptan responders [68]
Genetic variability-polymorphisms STin2 VNTR polymorphism of serotonin transporter gene could be an important genetic factor
to confer a higher risk of inconsistent response to triptans in migraine patients [69]
Mechanisms of receptor adaptation When an excess of mediator is present in the biophase, a process of desensitisation is activated,
which makes receptors refractory. This phenomenon can explain why a second tablet of
sumatriptan at 2 h does not increase initial efficacy and does not prevent or delay headache
recurrence [70]
Selection of the patient The patient must be capable to respond to the drug if we want a response. If the patient takes the
triptan for a tension-type headache, the response is improbable, since triptans are not effective
in episodic tension-type headache [71]
Placebo effect In clinical practice, a patient’s response to an active drug makes us wonder if this patient
responds well because of the medication (and its kinetic properties) or because of the placebo
effect (caused, for example, by the patient’s positive expectations and by the physician who
has prescribed the drug) [72]
Fluctuation of migraine The course of migraine can vary in years: changes in this disorder are likely to influence the
response to triptans [73]
Prophylactic treatments The use of prophylactic medications increases the consistency of response to triptans [10, 24]
Previous therapies In individuals with migraine, recent prior opioid use reduces triptan response [74]
Time of medication administration and severity
of the migraine attack
The response to triptans is higher and more complete if they are taken early, and when the pain
is of mild intensity [26]
J Headache Pain (2011) 12:5–12 9
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migraine, with oral (and maybe also nasal and rectal)
triptans, the importance of kinetic differences is already
low for the large variability observed (intersubjets, intra-
subjects, gender-related, in healthy volunteers, and in
migraine patients outside and during the attack). Further-
more, it is outweighed by the number and importance of
non-kinetic sources of variability (Table 4). Choosing an
oral triptan according to a mean pharmacokinetic param-
eter is not an efficient method, since it does not allow
choosing, with good probabilities of success, the most
appropriate triptan for each patient or to predict which
patient will respond to which drug.
Pharmacokinetic parameters are fundamental for the
efficacy of a drug, since they influence the arrival at the site
of action with the fit concentration. Nevertheless, if their
variation range is very large, the behaviour of a certain
drug becomes unforeseeable in that specific case. This is
why the physician must know the pharmacokinetics of each
triptan, but (since he will never have to treat the average
patient) also how and why kinetic parameters and the
response to the drug can vary in the patient. As a conclu-
sion, understanding variability means understanding the
complex relationships among physiology, pathology,
pharmacology, and clinical response.
If no new formulations are found allowing more pre-
dictable pharmacokinetics, similar problems are very likely
to be present also with new classes of drugs. It should,
therefore, be useful to become familiar with these issues.
The physician’s ability to manage uncertainty and unfore-
seeable aspects of therapy can strongly influence the rela-
tionship with the patient and, consequently, the long-term
results of migraine treatment.
Conflict of interest None.
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